Gene-environment Interactions and Brain Functional Connectivity in Attention Deficit Hyperactivity Disorder

Seoul National University

Status: Completed

Conditions: Attention Deficit Hyperactivity Disorder

Treatments: Drug: Methylphenidate

Study type: Interventional

Funder types: Other

Identifiers

NCT01912352

2010-0002283

Details and patient eligibility

About

The aims of the current study are to examine gene-environment interactions associated with norepinephrine (NE) system genes (ADRA2A, SLC6A2) in ADHD, and to evaluate whether genetic changes in norepinephrine pathway are associated with differences in functional connectivity of white matter fiber tracts, as measured by diffusion tensor imaging (DTI). Furthermore, this study aims to examine neurobiological markers, such as intermediate neuroimaging phenotypes or neuropsychological endophenotypes associated with the pathophysiology of ADHD. Through evaluating drug responses and side effects with the associated measures of clinical, neuropsychological and neuroimaging characteristics, investigators would like to investigate predictors of treatment response associated with NE system genes in ADHD.

Enrollment: 83 patients

Sex: All

Ages: 6 to 18 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of Attention-deficit Hyperactivity Disorder
• 6-18 years old

Exclusion criteria

• History of neurological diseases, including convulsive disorders or brain damage
• IQ below 70
• Pervasive developmental disorder (autism)
• Language difficulties or learning disorders (reading disorders, mathematics disorders and disorders of written expression).
• Tourette's syndrome
• Bipolar disorder
• Psychosis

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

83 participants in 1 patient group

Methylphenidate

Experimental group

Description:

Participants were treated with methylphenidate (ranging from to 63mg) for 8 weeks. Doses of methylphenidate were titrated depending on symptoms and adverse eff ects at the 2nd and 4th weeks of treatment.

Treatment:

Drug: Methylphenidate